<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05097638</url>
  </required_header>
  <id_info>
    <org_study_id>5884</org_study_id>
    <nct_id>NCT05097638</nct_id>
  </id_info>
  <brief_title>Lung Health After Tuberculosis: Clinical and Functional Assessment in Post Pulmonary Tuberculosis Egyptian Patients.</brief_title>
  <official_title>Lung Health After Tuberculosis: Clinical and Functional Assessment in Post Pulmonary Tuberculosis Egyptian Patients.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assiut University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assiut University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Some of pulmonary tuberculous patients who completed their medication course experience lung&#xD;
      function impairment&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Some of pulmonary tuberculous patients who completed their medication course experience lung&#xD;
      function impairment which may influence their quality of life. However, the pattern and&#xD;
      nature of post-tuberculosis lung impairment is still not identified. Thus, the aim of this&#xD;
      study was to determine the type and degree of lung physiology changes in previously treated&#xD;
      tuberculous patients which latter may affect their quality of life; thus helping clinicians&#xD;
      for early diagnosis of lung impairment, especially in tuberculous endemic areas.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 20, 2018</start_date>
  <completion_date type="Actual">February 4, 2020</completion_date>
  <primary_completion_date type="Actual">November 1, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Post tuberculosis lung functional impairment</measure>
    <time_frame>6 months</time_frame>
    <description>spirometry abnormality either: restrictive, obstructive, or mixed</description>
  </primary_outcome>
  <primary_outcome>
    <measure>post tuberculosis persistent clinical symptoms</measure>
    <time_frame>6 months</time_frame>
    <description>either cough , sputum , breathlessness, hemoptysis</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Grading of obstruction function:</measure>
    <time_frame>6 months</time_frame>
    <description>grading according to GOLD : mild , moderate , severe , very severe</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">210</enrollment>
  <condition>Pulmonary Tuberculoses</condition>
  <condition>Pulmonary Function; Newborn, Abnormal</condition>
  <arm_group>
    <arm_group_label>Cured pulmonary Tuberculosis patients</arm_group_label>
    <description>6 months after a completed course of anti-tuberculosis therapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>spirometry</intervention_name>
    <description>Patient do spirometry</description>
    <arm_group_label>Cured pulmonary Tuberculosis patients</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patient more than 18 years old had been newly diagnosed drug-sensitive first episode&#xD;
        pulmonary tuberculosis, confirmed by sputum smear microscopy were included in the study. He&#xD;
        completed an outpatient course of standard first line anti-tuberculosis therapy (6 months)&#xD;
        and declared as cured without radiological change over the past year (in comparable with&#xD;
        chest X-ray at the end of TB treatment).&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient completed an outpatient course of standard first line anti-tuberculosis&#xD;
             therapy and declared as cured&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Smoker (to avoid spirometry biases).&#xD;
&#xD;
          -  Extrapulmonary tuberculosis cases&#xD;
&#xD;
          -  Multidrug resistant tuberculosis&#xD;
&#xD;
          -  known contraindications to spirometry testing&#xD;
&#xD;
          -  Individuals with chest wall deformities or neuromuscular diseases&#xD;
&#xD;
          -  Patients who failed to achieve acceptability and reproducibility criteria of the&#xD;
             spirometry test&#xD;
&#xD;
          -  Defaulter cases or irregular treatment,&#xD;
&#xD;
          -  known coexisting chronic lung disease as history of asthma or interstitial lung&#xD;
             diseases&#xD;
&#xD;
          -  A history of illicit drug use&#xD;
&#xD;
          -  Patients with comorbidities: renal and hepatic insufficiency, heart diseases and&#xD;
             metabolic disorders.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Chest Department-faculty of medicine-Assuit university</name>
      <address>
        <city>Assuit</city>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 7, 2021</study_first_submitted>
  <study_first_submitted_qc>October 16, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 28, 2021</study_first_posted>
  <last_update_submitted>October 16, 2021</last_update_submitted>
  <last_update_submitted_qc>October 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Assiut University</investigator_affiliation>
    <investigator_full_name>Nermeen Aly Mahmoud Abdel Aleem</investigator_full_name>
    <investigator_title>Lecture in Chest and Tuberculosis Department, Faculty of Medicine</investigator_title>
  </responsible_party>
  <keyword>pulmonary Tuberculosis</keyword>
  <keyword>Spirometry</keyword>
  <keyword>Pulmonary Function</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tuberculosis</mesh_term>
    <mesh_term>Tuberculosis, Pulmonary</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

